Pipeline
Carna has leveraged its expertise in kinase biology to establish an innovative product pipeline focused on cancer and immune disorders. We achieve success by coupling our deep understanding of cell signaling with our extensive drug discovery expertise to generate therapeutics that inhibit kinases and provide new treatment options for patients with high unmet medical needs.
Science
Technology
Carna has developed a robust screening engine that makes it possible to identify new generation of kinase inhibitor drugs to treat patients afflicted with serious diseases.
Partnering
Carna is interested in partnering with pharmaceutical and biotechnology companies to develop our drug candidates. Carnaʼ s powerful kinase drug discovery engine drives our pipeline expansion and the establishment of high-value partnerships.
Our drug discovery programs begin with screening our vast lead-like compound library, followed by kinase profiling to select lead candidates and optimize chemistry to identify highly selective drug candidates.
Topics
- AS-1763, a next generation BTK inhibitor, demonstrates encouraging safety and efficacy in patients with B-cell malignancies in Phase 1b study
- New paper has been published in Bioorganic & Medicinal Chemistry Letters in collaboration with Prof. Naka of Hiroshima University
- Carna announces acceptance of a poster on AS-1763 for presentation at European Hematology Association (EHA) 2024
- Carna presented a poster on monzosertib at AACR Annual Meeting
- Updated Pipeline page